A Protocol to Monitor the Neurological Development of Infants With Exposure In-utero From Birth to Aged 15 Months in Tanezumab Clinical Studies at Investigational Sites Overseen by Schulman and Associates Institutional Review Board.
Latest Information Update: 13 Feb 2013
At a glance
- Drugs Tanezumab (Primary)
- Indications Cancer pain
- Focus Adverse reactions
- Acronyms NEONATAL MONITORING
- Sponsors Pfizer
Most Recent Events
- 05 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Nov 2012 Planned end date changed from 1 Sep 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 01 Oct 2012 Planned end date changed from 1 Sep 2012 to 1 Sep 2015 as reported by ClinicalTrials.gov record.